QSAR analysis of [(biphenyloxy)propyl] isoxazoles: Agents against coxsackievirus B3

Future Medicinal Chemistry

Volumn 3, Issue 1, 2011, Pages 15-27

  Muratov, Eugene N ^a,b   Varlamova, Ekaterina V ^a   Artemenko, Anatoly G ^a   Khristova, Tat'yana ^a   Kuz'min, Victor E ^a   Makarov, Vadim A ^c   Riabova, Olga B ^c   Wutzler, Peter ^d   Schmidtke, Michaela ^d  

^a A V BOGATSKY PHYSICO CHEMICAL INSTITUTE   (Ukraine)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 1 PHENYL 1H IMIDAZO[4,5 C]PYRIDINE; ISOXAZOLE DERIVATIVE; PLECONARIL; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; COXSACKIE VIRUS B3; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; HELA CELL; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VIRUS ISOLATION;

ANTIVIRAL AGENTS; COXSACKIEVIRUS INFECTIONS; DRUG DESIGN; ENTEROVIRUS B, HUMAN; HELA CELLS; HUMANS; ISOXAZOLES; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650674481     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.278     Document Type: Article

References (48)

1. Rollinger JM, Schmidtke M. The human rhinovirus: humanS-pathological impact, mechanisms of antirhinoviral agents and strategies for their discovery. Med. Res. Rev. DOI: 10.1002/med.20176 (2009) (Epub ahead of print).
2. Pallansch M, Roos R. Enteroviruses: spolioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Fields Virology Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA 840-893 (2007).
3. Wheeler DS, Kooy NW. A formidable challenge: the diagnosis and treatment of viral myocarditis in children. Crit. Care Clin. 19(3), 365-391 (2003).
4. Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. Circulation 119(19), 2615-2624 (2009).
5. Barnard DL. Current status of anti-picornavirus therapies. Curr. Pharm. Des. 12, 1379-1390 (2006).
6. de Palma AM, Vliegen I, de Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 28(6), 823-884 (2008).
7. Racaniello VR. Picornaviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA 796-839 (2007).
8. Rossmann MG, He Y, Kuhn RJ. Picornavirus-receptor interactions. Trends Microbiol. 10(7), 324-331 (2002).
9. Cox S, Buontempo PJ, Wright-Minogue J et al. Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies. Antivir. Res. 32(2), 71-79 (1996).
10. Hadfield AT, Diana GD, Rossmann MG. Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. Proc. Natl Acad. Sci. USA 96(26), 14730-14735 (1999).
11. Muckelbauer JK, Kremer M, Minor I et al. The structure of coxsackievirus B3 at 3.5 Å resolution. Structure 3(7), 653-667 (1995).
12. Zhang Y, Simpson AA, Ledford RM et al. Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. J. Virol. 78(20), 11061-11069 (2004).
13. Ledford RM, Patel NR, Demenczuk TM et al. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J. Virol. 78(7), 3663-3674 (2004).
14. Schmidtke M, Hammerschmidt E, Schuler S et al. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J. Antimicrob. Chemother. 56(4), 648-656 (2005).
15. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43(9), 2109-2115 (1999).
16. Hayden FG, Coats T, Kim K et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in Phase II clinical trials. Antivir. Ther. 7, 53-65 (2002).
17. Hayden FG, Herrington DT, Coats TL et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin. Infect. Dis. 36, 1523-1532 (2003).
18. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob. Agents Chemother. 49, 4492-4499 (2005).
19. Makarov VA, Riabova OB, Granik VG, Wutzler P, Schmidtke M. Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J. Antimicrob. Chemother. 55, 483-488 (2005).
20. Kuzmin VE, Artemenko AG, Muratov EN et al. Quantitative structure-activity relationship studies of [(biphenyloxy)propyl] isoxazole derivatives - human rhinovirus 2 replication inhibitors. J. Med. Chem. 50, 4205-4213 (2007).
21. Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antivir. Res. 81, 56-63 (2009).
22. Muratov EN, Kuzmin VE, Artemenko AG et al. HiT QSAR analysis of anti-coxsackievirus b3 activity of [(biphenyloxy) propyl]isoxazole derivatives. Antivir. Res. 78, A60-A61 (2008).
23. Kuzmin V, Artemenko A, Muratov E et al. QSAR analysis of cytotoxicity in HeLa cells. Antivir. Res. 78, A43 (2008).
24. Artemenko AG, Muratov EN, Atamanyuk DV et al. QSAR analysis of antimicrobial activity of 4-thiazolidone derivatives. QSAR Comb. Sci. 29, 194-205 (2009).
25. Artemenko AG, Muratov EN, Kuzmin VE et al. Identification of individual structural fragments of N,N-(bis-5-nitropyrimidyl) dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. J. Antimicrob. Chemother. 60(1), 68-77 (2007).
26. Kuzmin VE, Muratov EN, Artemenko AG, Gorb LG, Qasim M, Leszczynski J. The effect of nitroaromatics composition on their toxicity in vivo: Novel, efficient non-additive 1D QSAR analysis. Chemosphere 72, 1373-1380 (2008).
27. Kuzmin VE, Muratov EN, Artemenko AG, Gorb LG, Qasim M, Leszczynski J. The effects of characteristics of substituents on toxicity of the nitroaromatics: HiT QSAR study. J. Comp. Aid. Mol. Des. 22, 747-759 (2008).
28. Kuzmin VE, Muratov EN, Artemenko AG et al. Consensus QSAR modeling of phosphor-containing chiral AChE inhibitors. QSAR Comb. Sci. 28, 664-677 (2009).
29. Muratov EN, Artemenko AG, Kuzmin VE et al. Investigation of anti-influenza activity using hierarchic QSAR technology on the base of simplex representation of molecular structure. Antivir. Res. 65(3), A62-A63 (2005).
30. Kuzmin VE, Artemenko AG, Lozitsky VP et al. The analysis of structure- anticancer and antiviral activity relationships for macrocyclic pyridinophanes and their analogues on the basis of 4D QSAR models (simplex representation of molecular structure). Acta Biochim. Polon. 49, 157-168 (2002).
31. Kuzmin VE, Artemenko AG, Muratov EN. Hierarchical QSAR technology on the base of Simplex representation of molecular structure. J. Comp. Aid. Mol. Des. 22, 403-421 (2008).
32. Hasegawa K, Miyashita Y, Funatsu K. GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists. J. Chem. Inf. Comput. Sci. 37, 306-310 (1997).
33. Carhart RE, Smith DH, Venkataraghavan R. Atom pairs as molecular features in structure-activity studies. Definition and application. J. Chem. Inf. Comput. Sci. 25, 64-73 (1995).
34. Lindgren F, Geladi P, Rannar S, Wold S. Interactive variable selection (IVS) for PLS. Part 1: theory and algorithms. J. Chemometr. 8, 349-363 (1994).
35. Kubinyi H. Evolutionary variable selection in regression and PLS analyses. J. Chemometr. 10, 119-133 (1996).
36. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol. Inf. 29, 476-488 (2010).
37. Tropsha A, Golbraikh A. Predictive QSAR modeling workflow model applicability domains and virtual screening. Curr. Pharm. Des. 13, 3494-3504 (2007).
38. Tropsha A, Gramatica P, Gombar V. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 22, 69-77 (2003).
39. Jaworska J, Nikolova-Jeliazkova N, Aldenberg T. QSAR applicability domain estimation by projection of the training set in descriptor space: a review. Altern. Lab. Anim. 33, 445-459 (2005).
40. Muratov EN, Artemenko AG, Varlamova EV et al. Per aspera ad astra: application of Simplex QSAR approach in antiviral research. Future Med. Chem. 2, 1205-1226 (2010).
41. Polishchuk PG, Muratov EN, Artemenko AG, Kolumbin OG, Muratov NN, Kuzmin VE. Application of random forest approach to QSAR prediction of aquatic toxicity. J. Chem. Inf. Model. 49, 2481-2488 (2009).
42. Schmidtke M, Schnittler U, Jahn B, Dahse H, Stelzner A. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. J. Virol. Methods 95, 133-143 (2001).
43. Rannar S, Lindgren F, Geladi P, Wold S. A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: theory and algorithm. J. Chemometr. 8, 111-125 (1994).
44. Kuzmin VE, Artemenko AG, Lozitska RN et al. Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure. SAR QSAR Environ. Res. 16(3), 219-230 (2005).
45. Verma RP, Hansch C. Understanding human rhinovirus infections in terms of QSAR. Virology 359(1), 152-161 (2007).
46. Kuzmin VE, Artemenko AG, Muratov EN et al. QSAR analysis of anti-coxsackievirus B3 nancy activity of 2-amino-3- nitropyrazole[1,5-a] pyrimidines by means of Simplex approach. Antivir. Res. 74, A49-A50 (2007).
47. Fourches D, Muratov EN, Tropsha A. Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model. 50, 1189-1204 (2010).
48. Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 262, 175-182 (2009).